AstraZeneca PLC (AZN)vsWW International, Inc (WW)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
WW
WW International, Inc
$14.78
+0.03%
HEALTHCARE · Cap: $180.18M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 9121% more annual revenue ($61.37B vs $665.49M). AZN leads profitability with a 17.0% profit margin vs -15.2%. AZN appears more attractively valued with a PEG of 1.28. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
WW
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for WW.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 405 in profit
Safe zone — low bankruptcy risk
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Elevated debt levels
Expensive relative to growth rate
Revenue declined 14.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : WW
The strongest argument for WW centers on P/E Ratio, Price/Book, Return on Equity.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : WW
The primary concerns for WW are Market Cap, Debt/Equity, PEG Ratio. Debt-to-equity of 1.53 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while WW is a turnaround play — different risk/reward profiles.
WW carries more volatility with a beta of 1.06 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 39/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
WW International, Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
WW International, Inc. offers worldwide weight management products and services. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?